Prothena Corporation plc (PRTA) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

are in a listen-only mode. We will be facilitating a question and answer session towards the end of today's call. If at any time during the call you require assistance, please press star, then zero, and a coordinator will be happy to assist you. I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations at Perthena. Please proceed. Thank you operator. Good afternoon and everyone and welcome to today's call to review Procena's business progress, fourth quarter and full year 2023 financial results and 2024 financial guidance. Please review the press release we issued earlier today, which is available on our website at Procena.com and is also attached to a form 8-K filed today with the SEC. In addition, we are using supplemental slides, which are available on our investor website events and presentation section. On today's call, Dr. Gene Kinney, our President and Chief Executive Officer, will provide opening remarks, including an overview of Prothena's corporate and development strategy. Then Brandon Smith, our Chief Operating Officer, will provide an update on our pre-commercial progress for our wholly-owned Britannimab program, which is in phase three for the treatment of patients with Mayo stage four ALN mitosis. Dr. Hideki Garan, our Chief Medical Officer, will provide an update on our ongoing clinical programs. John Nguyen, our Chief Financial Officer and Chief Strategy Officer, will then discuss our 2023 financial results and 2024 financial guidance before turning it back to Gene for closing remarks, at which point we will open up the call for a Q&A session. Before we begin, I would like to remind you that during today's presentation, we will be making forward-looking statements that are subject to certain risks, uncertain...